Search company, investor...


Founded Year



Series C | Alive

About Infinovo

Infinovo is a China-based medical technology company that focuses on glucose monitoring for diabetes.

Headquarters Location

3rd Floor, 6th building No.888 Zhujiang Road

Nantong, Jiangsu, 226400,



Missing: Infinovo's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Infinovo's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Infinovo

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Infinovo is included in 4 Expert Collections, including Digital Health.


Digital Health

13,538 items


Medical Devices

8,605 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.



2,051 items


Health IT

7,901 items

Latest Infinovo News

UPDATE: ALR Technologies Announces Sales Guidance for Q4 2022, Q1 2023, and Completion of the GluCurve Pet CGM Manufacturing Agreement

Dec 29, 2022

Richmond, Virginia, UNITED STATES SINGAPORE, Dec. 29, 2022 (GLOBE NEWSWIRE) -- ALR Technologies SG Ltd. (“ALRT”) (OTCQB:ALRTF), the diabetes management company, today announced the completion of a long-term manufacturing and supply agreement with Infinovo Medical Co. Ltd (“Infinovo”) for the Continuous Glucose Monitor (CGM) hardware used in the GluCurve Pet CGM. The agreement gives ALRT the exclusive global rights to distribute the CGM hardware in the animal health market. Additionally, the Company announces it anticipates December and fourth quarter of 2022 sales to be in the range of $145,000 and $155,000. The Company expects Q1 2023 sales to be in the range of $450,000 to $600,000 with the possibility of an adjustment upwards subject to increased production capacity. “December reflects a turning point for ALRT as we look to close out the fiscal year with our first quarter of meaningful sales, along with an attractive gross profit,” said Sidney Chan, Chairman and CEO of ALRT. “We will be exhibiting the GluCurve Pet CGM at CES January 5th-8th and VMX (Veterinary Meeting and Expo) January 14th-18th which should bolster awareness around the Company and GluCurve. The number of available units will increase quarter over quarter throughout 2023 resulting in a significant rise in sales as it will enable our distribution partner, Covetrus, to launch GluCurve throughout the US, EU, and other key markets.” About Infinovo Medical Co. Ltd: Founded in 2016, Infinovo is an innovative medical technology company, focusing on developing an accurate and affordable CGM for patients which will be available for both Type 1 and Type 2 Diabetics. About ALR Technologies SG Ltd. ALRT is a data management company that developed the ALRT Diabetes Solution, a comprehensive approach to diabetes care that includes an FDA-cleared and HIPAA compliant diabetes management system that collects data directly from blood glucose meters and continuous glucose monitoring devices, and a patent pending Predictive A1C algorithm to track treatment success between lab reports and an FDA-cleared Insulin Dosing Adjustment program. The overall goal is to optimize diabetes drug therapies to drive improved patient outcomes. In addition, the animal health division of ALRT has developed the GluCurve Pet CGM; a solution to assist veterinarians better determine the efficacy of insulin treatments and to help to identify the appropriate dose and frequency of administration for companion animals, thereby delivering the same optimization of diabetic drug therapies to pets as to humans. More information about ALRT can be found at and . Investor Contact

Infinovo Frequently Asked Questions (FAQ)

  • When was Infinovo founded?

    Infinovo was founded in 2016.

  • Where is Infinovo's headquarters?

    Infinovo's headquarters is located at 3rd Floor, 6th building, Nantong.

  • What is Infinovo's latest funding round?

    Infinovo's latest funding round is Series C.

  • Who are the investors of Infinovo?

    Investors of Infinovo include Loyal Valley Capital, Hillhouse Capital Management, Yunfeng Capital, Qianhai Fund of Funds, Huimei Investment and 8 more.

  • Who are Infinovo's competitors?

    Competitors of Infinovo include BeatO, January, OrangeBiomed, Laxmi Therapeutic Devices, Onalabs, Levels, Dr.Diary, Beta Bionics, DiaMonTech, Tula Health and 21 more.

Compare Infinovo to Competitors

WaveForm Diabetes Logo
WaveForm Diabetes

WaveForm Diabetes is delivering connected diabetes solutions that empower people to live healthier lives.

Diabits Logo

Diabits develops an app that is a personalized diabetes management tool for people with type I and type II diabetes. Using an AI algorithm, the Diabits app builds a personalized model of user's blood sugar and predicts blood sugar levels up to an hour in advance.


Dr.Diary is a mobile-based blood glucose management solution, information portal, and community for diabetic patients.

Light Touch Technology

Light Touch Technology (LTT) develops non-invasive technology to assess blood glucose levels. The company has fused solid-state laser technology and optical parametric oscillation to develop a high-brightness mid-infrared laser that is brighter than conventional products.

Tula Health

Tula Health is a personalized digital health platform that continuously and noninvasively monitors blood glucose and key health metrics through its patent protected BioCheck™ technology.

GraphWear Technologies

GraphWear Technologies develops low-cost graphene-enhanced flexible sensors measuring blood sugar, dehydration, and fat burning.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.